About: Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis
Creator	Ahmed, Ibrahim Hirayama, Kenji Memish, A Nguyen, \| Tran, \| Ali, \| Lu, \| Mostafa, \| Sahar, \| Sarah, \| Ahmed, \| Altibi, M Dat, Minh Elabd, Samy Ghazy, Abdelmotaleb Huy, Tien Kamel, Mohamed Le Van Thanh, \| Morra, Mostafa Mostafa, Reda Omrani, S Samreen Fathima, \| Thy, Ngoc Vu, Le Vuong, Lam Ziad, \|
Source	Medline; PMC
abstract	Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus. Because of lack of vaccination, various studies investigated the therapeutic efficacy of antiviral drugs and supportive remedies. A systematic literature search from 10 databases was conducted and screened for relevant articles. Studies reporting information about the treatment of MERS coronavirus infection were extracted and analyzed. Despite receiving treatment with ribavirin plus IFN, the case fatality rate was as high as 71% in the IFN‐treatment group and exactly the same in patients who received supportive treatment only. Having chronic renal disease, diabetes mellitus and hypertension increased the risk of mortality (P < .05), and chronic renal disease is the best parameter to predict the mortality. The mean of survival days from onset of illness to death was 46.6 (95% CI, 30.5‐62.6) for the IFN group compared with 18.8 (95% CI, 10.3‐27.4) for the supportive‐only group (P = .001). Delay in starting treatment, older age group, and preexisting comorbidities are associated with worse outcomes. In conclusion, there is no difference between IFN treatment and supportive treatment for MERS patients in terms of mortality. However, ribavirin and IFN combination might have efficacious effects with timely administration and monitoring of adverse events. Large‐scale prospective randomized studies are required to assess the role of antiviral drugs for the treatment of this high mortality infection.
has issue date	2018-04-17(xsd:dateTime)
bibo:doi	10.1002/rmv.1977
bibo:pmid	29664167
has license	no-cc
sha1sum (hex)	df3bdfaf324a1ca92d08013c1a6e001428cdd8c1
schema:url	https://doi.org/10.1002/rmv.1977
resource representing a document's title	Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis
has PubMed Central identifier	PMC7169085
has PubMed identifier	29664167
schema:publication	Rev Med Virol
resource representing a document's body	covid:df3bdfaf324a1ca92d08013c1a6e001428cdd8c1#body_text
is schema:about of	named entity 'high' named entity 'conducted' named entity 'ribavirin' named entity 'Despite' named entity 'CAUSED BY' named entity 'VARIOUS' named entity 'RIBAVIRIN' named entity 'RELEVANT' named entity 'MERS coronavirus' named entity 'patients' named entity 'Studies' named entity 'investigated' named entity 'treatment group' named entity 'coronavirus' named entity 'IFN' named entity 'survival time' named entity 'immunoglobulins' named entity 'inclusion and exclusion criteria' named entity 'mortality rate' named entity 'data extraction' named entity 'observational studies' named entity 'CART' named entity 'statistically significant' named entity 'ribavirin' named entity 'tenofovir' named entity 'beta-1a' named entity 'case reports' named entity 'Qatar' named entity 'clinical trials' named entity 'Kaplan-Meier' named entity 'ribavirin' named entity 'creatinine clearance' named entity 'oseltamivir' named entity 'ribavirin' named entity 'inotropes' named entity 'June 2015' named entity 'mortality rate' named entity 'vasopressors' named entity 'ribavirin' named entity 'antiviral therapy' named entity 'prone position' named entity 'data analysis' named entity 'corticosteroids' named entity 'systematic review' named entity 'renal replacement therapy' named entity 'chronic kidney disease' named entity 'supportive care' named entity 'classification and regression tree' named entity 'ritonavir' named entity 'antiviral treatment' named entity 'study design' named entity 'clinical data' named entity 'beta-1a' named entity 'oseltamivir' named entity 'supportive treatment' named entity 'significant difference'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software